Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design-Reference-Cited by-同舟云学术

Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Published:2015-01-13 Issue:4 Volume:43 Page:490-509
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Lee Caroline A.,O’Connor Meeghan A.,Ritchie Tasha K.,Galetin Aleksandra,Cook Jack A.,Ragueneau-Majlessi Isabelle,Ellens Harma,Feng Bo,Taub Mitchell E.,Paine Mary F.,Polli Joseph W.,Ware Joseph A.,Zamek-Gliszczynski Maciej J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference216 articles.

1. Colchicine toxicity precipitated by interaction with sunitinib

2. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration;Adkison;J Pharm Sci,2010

3. TheABCG2C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects

4. Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents

5. Flavonoid Structure-Activity Studies Identify 6-Prenylchrysin and Tectochrysin as Potent and Specific Inhibitors of Breast Cancer Resistance Protein ABCG2

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human enteroid monolayers as a potential alternative for Ussing chamber and Caco-2 monolayers to study passive permeability and drug efflux;European Journal of Pharmaceutical Sciences;2024-10

2. Breast Cancer Resistance Protein: Structure, Localization, Functions, Significance for Rational Pharmacotherapy;I.P. Pavlov Russian Medical Biological Herald;2024-07-10

3. A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants;Journal of Pharmacology and Experimental Therapeutics;2024-01-31

4. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

5. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide;Biomedicine & Pharmacotherapy;2024-01